Score Breakdown
Below average.
Tempus AI is a genuinely innovative healthcare data platform with a differentiated multimodal dataset and strong positioning in precision oncology diagnostics. However, the stock trades at ~5.9x TTM revenue despite deeply negative FCF (-32% margin), questionable revenue quality (related-party deals with CEO-controlled Pathos, potential round-tripping with SoftBank JV), massive SBC (16% of revenue), 7.5% annual dilution, heavy insider selling, securities fraud lawsuits, and a CEO with a checkered track record (Groupon). The adjusted EBITDA turning positive is misleading — it excludes ~$200M+ in SBC annually and real cash burn remains severe. With 20.6% short interest, ~22 months cash runway, and the need for continued equity issuance, the risk/reward is unfavorable at current valuation. The stock needs to prove sustainable, high-quality cash generation before deserving a premium multiple, and that proof is 2+ years away at minimum.
Negative cash flow. Can't value it.
Some yellow flags.
Slow bleed.
Execs cashing out.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The core bear thesis, solidified by a Spruce Point Capital report, argues that Tempus is an 'AI-washing' story; in 2024, only ~2% of revenue ($12.4M of $693M) was derived from actual AI applications, with the bulk coming from lower-margin genomic testing. Skeptics point to a deeply negative EPS (-$5.16 TTM) and a negative intrinsic value, suggesting the business model is a 'cash-burning' machine rather than a sustainable tech platform (StockInvest, May 2025; Weiss Ratings, Jan 2026).
🔍 What's In The SEC Filings
Tempus utilizes complex related-party licensing and inorganic growth to meet revenue targets while sustaining operations through continuous equity dilution and high-interest debt.
Circular revenue with Pathos AI (CEO-controlled entity) and potential non-cash settlement.
“Pathos, in its sole discretion, may pay up to 50% of the data license fees owed to the Company in shares of Pathos’ Series D Preferred Stock.”
Revenue is recognized on the P&L but may be settled in illiquid, private equity of another entity controlled by the CEO, potentially inflating earnings without generating cash.
Assumption of 'dead' cloud usage liabilities through acquisition.
“The Company also assumed $39.5 million of remaining purchase commitments under Paige's Microsoft Azure cloud services agreement in excess of forecasted usage.”
By acquiring Paige, Tempus took on $39.5M in contractual obligations for cloud services that are explicitly noted as being in excess of what they actually need, acting as a direct cash drain.
Heavy reliance on 'At The Market' (ATM) offerings to fund operations.
“the Company sold 2,381,895 shares under the ATM at a weighted average price of $83.97 per share for total proceeds of $195.5 million... approximately $300.0 million remained available for sale.”
The company is using public markets as a credit card, selling shares directly into the market to offset significant operational losses, leading to immediate per-share value erosion.
Executive compensation tied heavily to aggressive revenue growth targets.
“50% of the PSUs are subject to a performance condition, which is based on the Company’s compound revenue growth ('CRG').”
Management is incentivized to prioritize top-line revenue through any means (acquisitions, related-party deals) to trigger stock vesting, regardless of the underlying profitability or cash flow quality.
The intrinsic value should be discounted by at least 20-30% to account for revenue quality issues (related-party/non-cash components) and the high probability of ongoing share count expansion via the $300M remaining ATM and convertible note dilution.
The 'round-tripping' nature of the Pathos and SoftBank JV (SB Tempus) revenue is concerning; Tempus provides capital to JVs which then pay Tempus back in licensing fees, potentially creating 'phantom' revenue growth.